|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCDH19 |
Gene summary for PCDH19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCDH19 | Gene ID | 57526 |
| Gene name | protocadherin 19 | |
| Gene Alias | DEE9 | |
| Cytomap | Xq22.1 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | B3KU71 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57526 | PCDH19 | LZE7T | Human | Esophagus | ESCC | 9.10e-14 | 8.70e-01 | 0.0667 |
| 57526 | PCDH19 | P2T-E | Human | Esophagus | ESCC | 2.96e-13 | 3.02e-01 | 0.1177 |
| 57526 | PCDH19 | P4T-E | Human | Esophagus | ESCC | 9.41e-09 | 2.81e-01 | 0.1323 |
| 57526 | PCDH19 | P5T-E | Human | Esophagus | ESCC | 1.29e-04 | 4.21e-02 | 0.1327 |
| 57526 | PCDH19 | P8T-E | Human | Esophagus | ESCC | 1.26e-03 | 1.47e-01 | 0.0889 |
| 57526 | PCDH19 | P9T-E | Human | Esophagus | ESCC | 3.26e-07 | 1.04e-01 | 0.1131 |
| 57526 | PCDH19 | P10T-E | Human | Esophagus | ESCC | 1.20e-11 | 1.81e-01 | 0.116 |
| 57526 | PCDH19 | P26T-E | Human | Esophagus | ESCC | 1.44e-35 | 7.81e-01 | 0.1276 |
| 57526 | PCDH19 | P27T-E | Human | Esophagus | ESCC | 3.28e-06 | 1.14e-01 | 0.1055 |
| 57526 | PCDH19 | P32T-E | Human | Esophagus | ESCC | 8.11e-04 | 1.96e-01 | 0.1666 |
| 57526 | PCDH19 | P39T-E | Human | Esophagus | ESCC | 3.90e-02 | 5.04e-02 | 0.0894 |
| 57526 | PCDH19 | P40T-E | Human | Esophagus | ESCC | 3.19e-03 | 9.95e-02 | 0.109 |
| 57526 | PCDH19 | P42T-E | Human | Esophagus | ESCC | 8.96e-05 | 9.83e-02 | 0.1175 |
| 57526 | PCDH19 | P47T-E | Human | Esophagus | ESCC | 1.85e-02 | 6.77e-02 | 0.1067 |
| 57526 | PCDH19 | P52T-E | Human | Esophagus | ESCC | 2.53e-03 | 8.85e-02 | 0.1555 |
| 57526 | PCDH19 | P74T-E | Human | Esophagus | ESCC | 1.56e-08 | 2.75e-01 | 0.1479 |
| 57526 | PCDH19 | P83T-E | Human | Esophagus | ESCC | 1.46e-05 | 1.94e-01 | 0.1738 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCDH19 | SNV | Missense_Mutation | c.3274C>A | p.Arg1092Ser | p.R1092S | Q8TAB3 | protein_coding | deleterious_low_confidence(0) | benign(0.027) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| PCDH19 | SNV | Missense_Mutation | c.2423N>T | p.Thr808Ile | p.T808I | Q8TAB3 | protein_coding | tolerated(0.38) | probably_damaging(0.991) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| PCDH19 | SNV | Missense_Mutation | rs765066118 | c.2319G>T | p.Lys773Asn | p.K773N | Q8TAB3 | protein_coding | tolerated(0.23) | probably_damaging(0.991) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCDH19 | SNV | Missense_Mutation | c.859G>A | p.Glu287Lys | p.E287K | Q8TAB3 | protein_coding | deleterious(0) | benign(0.207) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PCDH19 | SNV | Missense_Mutation | c.739N>C | p.Val247Leu | p.V247L | Q8TAB3 | protein_coding | tolerated(1) | benign(0.073) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PCDH19 | SNV | Missense_Mutation | rs757057837 | c.3203N>A | p.Pro1068His | p.P1068H | Q8TAB3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PCDH19 | SNV | Missense_Mutation | c.2710C>A | p.Leu904Met | p.L904M | Q8TAB3 | protein_coding | tolerated(0.08) | probably_damaging(0.996) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PCDH19 | SNV | Missense_Mutation | c.856N>T | p.Arg286Cys | p.R286C | Q8TAB3 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AR-A1AW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |
| PCDH19 | SNV | Missense_Mutation | c.466C>G | p.Pro156Ala | p.P156A | Q8TAB3 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-B6-A0X0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PCDH19 | SNV | Missense_Mutation | c.1524C>G | p.Ile508Met | p.I508M | Q8TAB3 | protein_coding | deleterious(0.01) | probably_damaging(0.938) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |